TNP-2092 for injection

DRUG3 trials

Sponsors

TenNor Therapeutics Inc., TenNor Therapeutics (Zhongshan) Limited

Conditions

Acute Bacterial Skin and Skin Structure Infection (ABSSSI)Periprosthetic Joint Infection (PJI)Prosthetic Joint Infection (PJI)Prosthetic Joints Infection (PJI)

Phase 1

Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants

CompletedNCT06394518

TenNor Therapeutics Inc.Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Prosthetic Joints Infection (PJI)

Start: 2022-07-07End: 2023-02-24Updated: 2024-05-01

A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants

RecruitingNCT06889701

TenNor Therapeutics Inc.Periprosthetic Joint Infection (PJI)

Start: 2025-04-03End: 2027-01-01Target: 33Updated: 2026-10-19

Phase 2

A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants

RecruitingNCT07858916

TenNor Therapeutics (Zhongshan) LimitedProsthetic Joint Infection (PJI)

Start: 2026-10-21End: 2028-03-01Target: 40Updated: 2026-10-28

Related Papers

P-1064. Safety, Tolerability, and Pharmacokinetics of Rifaquizone for Injection in Healthy Participants in China: A Single-center, Double-blind, Randomized, Placebo-controlled, Phase 1 Bridge Study

Open Forum Infectious Diseases2025-01-291 citations